As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.
Similar Posts
Tower Laboratories Ltd. – 717456 – 12/23/2025
CGMP/Finished Pharmaceuticals/AdulteratedFDA use of Real-World Evidence in Regulatory Decision Making
The studies presented in the accompanying tables exemplify instances in which the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) applied RWE in regulatory decision-making processes since 2011.Pain and Arthritis Products Containing Hidden Ingredients
Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.Import Alerts for Certain Olympus Medical Devices Manufactured in Japan – Letter to Health Care Providers
The U.S. Food and Drug Administration (FDA) is alerting health care providers about import alerts for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation (Olympus) and its subsidiaries.FDA’s Actions to Address Unapproved Thyroid Medications
FDA’s Actions to Address Unapproved Thyroid MedicationsWound and Burn Dressing Recall: Integra LifeSciences Removes Certain MediHoney and CVS Wound and Burn Products
Integra is removing certain Wound and Burn Dressing products that may have breached sterile barriers.